What Is T1c Breast Cancer? Staging, Treatment, and Prognosis

T1c breast cancer is a small, early-stage cancer, with a main tumor roughly the size of a grape or smaller.¹ On its own, that makes it one of the most treatable findings in breast cancer, and most people diagnosed at this size go on to live long lives after treatment. The label describes size only, though. What really shapes your treatment is the kind of cancer cells the tumor is made of.

What T1c Means on Your Report

T1c means the tumor is larger than 10 millimeters but not larger than 20 millimeters.² In centimeters, that is more than 1 cm and not more than 2 cm.³ The T1 category is split into smaller groups: T1a is up to 5 mm, and T1b is over 5 mm up to 10 mm. That makes T1c the biggest of the T1 groups. Anything over 2 cm becomes T2.

Your report uses a three-part code. T is tumor size, N is whether lymph nodes contain cancer, and M is whether the cancer has spread to distant organs. A report reading T1c N0 M0 describes a 1 to 2 cm tumor with no cancer in the nodes and no distant spread. That combination falls in stage I, the earliest invasive stage. T1c is also the most common T1 size: in one large group of small cancers, about 63% were T1c.⁴

A small “p” before T1c means the pathologist measured the tumor on the tissue removed in surgery. A “c” prefix means the size came from an exam or imaging before surgery. The measured size in millimeters is usually printed nearby, and it should be more than 10 and no more than 20. It’s reasonable to ask your team which measurement your stage is based on. Imaging and the final measurement can differ, so a stage given before surgery can shift once the tumor is removed and measured directly.

Outlook and Survival for T1c Breast Cancer

Among people with T1 breast cancers, about 97% had not died of breast cancer 5 years later, and at 10 years that figure was about 95%.⁵ Overall survival, which counts deaths from any cause, was about 84% at 10 years. That lower number largely reflects age and other illnesses rather than the cancer itself.⁶ In one large study, overall survival did not differ between T1a, T1b and T1c tumors.⁷

Within T1, biology matters more than the exact size. Only the tiniest tumors, under about 5 mm, tend to be consistently low-risk.⁸ T1b and T1c tumors more often include faster-growing types, including triple-negative cancers.⁹ So two T1c cancers of the same size can carry quite different risks.

Survival numbers describe large groups of people treated in past years, not your personal result. Once your tumor type and lymph node results are known, your team can give you a more personal estimate.

Why Tumor Type Matters More Than Size

Hormone receptor-positive (ER/PR-positive) cancers grow in response to estrogen or progesterone, and they are the most common type. HER2-positive cancers make too much of a growth protein called HER2. Triple-negative cancers have none of these three markers. In one large group of small, node-negative cancers, about 66% were hormone-positive and HER2-negative, about 20% were HER2-positive, and 14% were triple-negative.¹⁰

In those small, node-negative cancers, tumor type predicted recurrence better than tumor size did.¹¹ About 94% of hormone-positive, HER2-negative patients were free of invasive disease at 5 years, compared with about 91% for triple-negative.¹² Hormone-positive cancers also had better breast cancer survival than hormone-negative ones at every tumor size, while triple-negative cancers carried the highest risk across all sizes.¹³ In another group, triple-negative tumors were about 4.5 times as likely to come back as hormone-positive HER2-negative ones.¹⁴

To find your subtype, look on the pathology report for ER, PR and HER2 results, often listed as positive or negative with percentages. HER2 may appear as a score of 0, 1+, 2+ or 3+. A 3+ is positive, and a 2+ needs a further test to settle it. These results usually arrive with the biopsy report or soon after. A small triple-negative or HER2-positive tumor may get more treatment than a larger hormone-positive one, because size and type are read together.

Checking the Lymph Nodes

In a sentinel lymph node biopsy, the surgeon removes the first one to three nodes that drain the breast and checks them for cancer. A dye or tracer injected near the tumor shows which nodes those are. They come out through a small cut in the armpit, usually during the breast surgery itself. Results may come during the operation or a few days later. Taking only a few nodes carries a lower risk of arm swelling than removing many.

About 24% of T1c cancers have cancer in the sentinel node, compared with about 4% of T1a and 49% of T2.¹⁵ Younger age, higher grade, tumor location, cancer type and cancer in nearby vessels all raise the chance of node spread.¹⁶ If the nodes are positive, the stage rises and more treatment is often offered.

N0 means no cancer was found in the nodes. Tiny clusters of cells may be reported separately and are sometimes treated differently.

Surgery Lumpectomy or Mastectomy

A lumpectomy removes the tumor along with a margin of normal tissue and keeps the breast. A mastectomy removes the whole breast. In small, node-negative triple-negative cancer, the cancer came back in the breast area in about 4% of people after lumpectomy with radiation and 5% after mastectomy at 5 years.¹⁷ Spread elsewhere and survival were about the same with either surgery.¹⁸

A 1 to 2 cm tumor is usually small enough for lumpectomy. Choosing it usually means agreeing to several weeks of radiation afterward. Mastectomy may be suggested when there are several tumors in the breast or a strong genetic risk. If you’re considering mastectomy, reconstruction can be discussed before the operation.

After surgery, the pathologist checks that the edges of the removed tissue, the margins, are clear of cancer. A positive margin may mean a second, smaller operation. Your final tumor size and node status come from this tissue.

Radiation After Surgery

Radiation after lumpectomy targets any cancer cells left behind in the breast. In women 70 and over with hormone-positive T1 cancers, radiation was linked to about 25% lower risk of dying.¹⁹ In older women with hormone-negative cancer after lumpectomy, 5-year breast cancer survival was about 93% with radiation and 85% without.²⁰

Each session takes only minutes and is given on weekdays, often over 3 to 5 weeks. Shorter courses are common for early cancers. Skin redness and tiredness are the usual side effects.

Hormone Therapy and the Recurrence Score

Hormone therapy uses pills such as tamoxifen or aromatase inhibitors to block estrogen’s effect, usually for at least 5 years. In T1c hormone-positive, HER2-negative cancer, 5-year disease-free survival was about 95% with hormone therapy and 78% without.²¹ Taking aromatase inhibitors beyond 5 years lowered recurrence and new cancer in the other breast but did not lengthen life, and longer use brought more bone problems.²²

Hot flashes, joint aches and mood changes are common on these pills. Aromatase inhibitors are used mainly after menopause, and bone density scans may be advised. Stopping early raises the risk of recurrence, so it’s better to report side effects to your team, who may be able to switch you to a different pill.

The Oncotype DX Recurrence Score tests genes in the tumor and gives a number from 0 to 100 that predicts the chance of the cancer returning. The test runs on tissue already removed, so there’s no extra procedure, and results take a couple of weeks. A score of 26 or higher is usually considered high, and chemotherapy plus hormone therapy is offered.²³ In T1b and T1c cancers, though, a clear survival gain from chemo showed in scores above 30, not in scores of 26 to 30 or in low-grade tumors.²⁴ For high-grade small tumors, the test should be strongly considered.²⁵

Treatment for HER2-Positive T1c Cancer

Trastuzumab is a drug that targets the HER2 protein. In T1c HER2-positive cancer, treated patients had clearly better disease-free survival than untreated ones.²⁶ Paclitaxel plus trastuzumab gives excellent long-term results in node-negative HER2-positive cancer.²⁷ Another option, trastuzumab emtansine, kept about 98% free of invasive disease at 3 years, with less nerve damage and hair loss.²⁸

Paclitaxel is often given weekly for 12 weeks along with trastuzumab. Trastuzumab then continues for about a year in total. Because it can affect heart function, you’ll have heart scans during treatment. If the cancer is also hormone-positive, hormone pills follow.

Treatment for Triple-Negative T1c Cancer

Triple-negative cancer has no hormone or HER2 target, so chemotherapy is the main added treatment. In node-negative T1c triple-negative cancer, survival was about 93% with chemo versus 75% without.²⁹ Chemo lowered the risk of death by nearly half in T1c triple-negative cancer.³⁰ Those given chemo before surgery whose tumor did not fully disappear did worse.³¹ For T1c, chemo is often given before surgery, which shows how the tumor responds. Leftover cancer can lead to extra treatment afterward. Ask which order your team recommends and why.

Questions to Ask Your Care Team

Is my stage based on imaging or the removed tissue?
What are my ER, PR and HER2 results?
What grade is the tumor?
Are my nodes clear?
Would a recurrence score change my plan?
Am I eligible for a trial testing lighter treatment, such as the ETNA trial for small triple-negative tumors?³²

Bring a copy of your pathology report to appointments, and bring someone along to take notes. If results seem unclear, you can ask for a second pathology review. Ask, too, how follow-up scans will be scheduled.